Metsera (NASDAQ:MTSR) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Metsera (NASDAQ:MTSR) from a hold rating to a sell rating in a research report released on Sunday morning.

MTSR has been the topic of several other research reports. Bank of America raised their price objective on Metsera from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 28th. Wells Fargo & Company began coverage on Metsera in a report on Friday, June 20th. They set an “overweight” rating and a $65.00 price objective on the stock. Guggenheim lifted their target price on Metsera from $56.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, June 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Metsera in a report on Wednesday, September 3rd. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $63.50.

Metsera Stock Performance

MTSR stock opened at $36.72 on Friday. Metsera has a 52-week low of $12.30 and a 52-week high of $47.40. The stock’s fifty day simple moving average is $35.06 and its 200-day simple moving average is $28.71.

Metsera (NASDAQ:MTSR) last posted its quarterly earnings data on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MTSR. Alphabet Inc. acquired a new position in shares of Metsera during the first quarter worth about $135,059,000. T. Rowe Price Investment Management Inc. acquired a new position in shares of Metsera during the first quarter worth about $78,748,000. Wellington Management Group LLP acquired a new position in shares of Metsera during the first quarter worth about $65,382,000. Alpha Wave Global LP acquired a new position in shares of Metsera during the first quarter worth about $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of Metsera during the first quarter worth about $42,395,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.